Modern approaches to evaluating the effectiveness of treatment of chronic heart failure


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The efficacy of therapy for patients with chronic heart failure, a new combination drug valsartan/sacubitrile according to the levels of biomarkers ST2 and NT-proBNP was evaluated. In all patients of the study group, valsartan/sacubitrile therapy improved the NYHA functional class, in the control group - only in 75%. The dynamics of indicators of biomarkers ST2 and NT-proBNP coincided with the improvement of the clinical status of patients against the background of therapy, and to a greater extent this trend reflects the indicator NT-proBNP.

全文:

受限制的访问

参考

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Potekhin N.P., Fursov A.N., Kazakov S.P., Putkov S.B., Pestovskaya O.R., Lyapkova N.B., Zakharova E.G., Makeeva T.G., Vereshchagina A.V., 2019


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 01975 от 30.12.1992.